A Study on the Inhibitory Effect of Polysaccharides from Radix Ranunculus Ternati on Human Breast Cancer MCF-7 Cell Lines

The objective of this paper was to study the in vitro anti-breast cancer activity of polysaccharides from Radix ranunculus ternati. Different concentrations of polysaccharide extracts were selected, and MTT assay and flow cytometry (FCM) were used to investigate their growth-inhibitory and apoptosis-inducing effects on human breast cancer MCF-7 cell lines. Radix ranunculus ternati polysaccharides had varying degrees of effects on the growth of human breast cancer MCF-7 cell lines, and the differences were significant compared with the blank control group. FCM showed that the polysaccharides can induce apoptosis. In addition, it can also enhance NK cell activity. Radix ranunculus ternati polysaccharides have a relatively good in-vitro anti-breast cancer activity.     

CPAP对小儿重症肺炎的疗效分析

目的：探讨小儿重症肺炎采用CPAP治疗的临床效果。方法本次共选择80例重症肺炎患儿做研究对象，均为我院2012年8月~2013年8月收治，采用数字表抽取法随机分组，就儿内科常规治疗方案（对照组，n=40）与加用CPAP治疗（观察组，n=40）临床效果进行比较。结果观察组选取病例经统计示临床总有效率为95%，显著高于对照组75%，差异有统计学意义（P＜0.05）。观察组气促、胸骨凹陷、发绀、肺部啰音缓解、平均住院天数均少于对照组，差异有统计学意义（P＜0.05）。两组疗前PaO2无明显差异，疗后PaO2均明显升高，观察组高于对照组升高幅度（P＜0.05）。结论小儿重症肺炎采用CPAP治疗，可显著改善预后，消除临床症状，加快患儿康复进程，具有非常积极的应用价值。     

系统免疫炎症指数在胰腺导管腺癌患者Whipple术后总体生存率中的预测价值

目的研究系统免疫炎症指数(SII)在胰腺导管腺癌患者Whipple术后总体生存率中的预测价值。方法回顾性分析2010年1月1日至2017年12月31日在郑州大学第一附属医院进行Whipple术的胰腺导管腺癌患者临床资料,计算SII值。取SII最佳截断值为900,以900为界值将所有患者分为低SII组(SII≤900)和高SII组(SII>900),应用Kaplan-Meier法绘制生存曲线,采用log-rank检验对两组患者的总生存时间进行分析,采用Cox风险回归模型对各项临床病理参数进行单因素分析,并对具有统计学意义的指标进行多因素分析。结果共纳入135例患者,其中男性78例,女性57例,年龄28.0~76.0(56.6±8.8)岁。低SII组纳入92例,年龄(56.9±9.2)岁,男性53例,女性39例;高SII组纳入43例,年龄(56.1±7.9)岁,男性25例,女性18例。低SII组和高SII组两组中位生存时间分别为32.7个月(95%CI:28.4~37.0)和24.4个月(95%CI:21.4~27.4),低SII组胰腺导管腺癌患者生存率高于和高SII组,差异有统计学意义(P<0.05)。在单因素生存分析中,胰腺导管腺癌患者术后总生存期与高SII(HR=2.047,95%CI:1.354~3.096)、R1切缘(HR=2.595,95%CI:1.663~4.048)、淋巴结阳性率>20%(HR=3.244,95%CI:1.888~5.573)、区域淋巴结(N1)(HR=3.061,95%CI:1.993~4.702)有关(均P<0.05)。多因素Cox回归分析显示,高SII(HR=1.672,95%CI:1.094~2.555)、R1切缘(HR=2.167,95%CI:1.274~3.685)、淋巴结阳性率>20%(HR=2.631,95%CI:1.309~5.285)是影响胰腺导管腺癌患者Whipple术后总生存期的独立危险因素(P<0.05)。结论SII是胰腺导管腺癌患者术前可获得的独立预后因子,在预测胰腺导管腺癌患者行Whipple术后总生存期方面有一定指导意义。     

麝香保心丸与硝酸异山梨酯联合治疗无症状性心肌缺血的效果研究

目的探讨无症状性心肌缺血患者使用麝香保心丸与硝酸异山梨酯联合治疗后的临床效果。方法选择来我院就诊的无症状性心肌缺血患者72例作为本次研究对象，随机分为两组。观察组（n=36）采用麝香保心丸联合硝酸异山梨酯进行治疗，对照组（n=36）采用硝酸异山梨酯进行治疗，对两组患者的心电图心肌缺血改善情况及血脂、血液动力学观察指标进行对比分析。结果观察组患者与对照组比较，心电图缺血改善情况中有效率明显较高，两组差异具有显著性（P〈0．05）。治疗后观察组患者的全血黏度高切值、全血黏度低切值、血浆比黏度、TG、TC均显著降低，与对照组治疗后比较改善情况明显较好（P〈0．05）。所有患者治疗后均未发现不良情况。结论无症状性心肌缺血患者在采用麝香保心丸联合硝酸异山梨酯治疗后能够收到较好的临床效果。可以在临床推广应用。     

II导联RWPT标准鉴别宽QRS波的早搏

目的探讨应用Ⅱ导联R波峰时间（RWPT）法对宽QRS波早搏的鉴别诊断价值。方法对已确诊的192例宽QRS波早搏患者，计算应用Ⅱ导联RwPr法对宽QRS波诊断的准确率。结果192例宽QRS波早搏患者中，已确诊的室性早搏130例，室上性早搏伴室内差异传导62例。应用Ⅱ导联RWPT法再鉴别其激动是室性还是室上性伴室内差异传导，发现真阳性112例、假阳性8例、真阴性54例、假阴性18例；敏感度85．38％，特异度87．00％，阳性预测值93．33％，阴性预测值76．39％，准确度86．46％。结论应用Ⅱ导联RWPT法鉴别宽QRS波早搏有较高的敏感度、特异度。     

A Phase II Study of CLAG Regimen Combined With Imatinib Mesylate for Relapsed or Refractory Acute Myeloid Leukemia

IntroductionNo standard salvage chemotherapy regimen is available for relapsed or refractory (RR) acute myeloid leukemia (AML). Preclinical data have suggested synergy in vitro between cytarabine and imatinib mesylate (IM) on AML cell growth inhibition. After demonstrating the safety and feasibility in a phase I study, we conducted a phase II clinical study of CLAG (cladribine, cytarabine, granulocyte colony-stimulating factor) regimen combined with IM for patients with RR-AML.Patients and MethodsWe performed a single-institution 2-stage phase II study. The primary endpoint was the remission rate measured using the standard AML response criteria. The secondary endpoints included overall survival (OS) and progression-free survival (PFS).ResultsFrom August 2009 to April 2011, 38 patients were treated at the Moffitt Cancer Center. Their median age was 62 years (range, 26-79 years). Of the 38 patients, 7 (18%) had refractory AML, 19 (50%) had early relapse, and 12 (32%) had late relapse. At the original diagnosis, only 2 patients had favorable risk factors, 18 had intermediate risk, and 16 had poor risk; for 2 patients, the karyotype was missing. The overall response rate for all 38 evaluable patients was 37%. The median OS was 11.1 months (95% CI, 4.8-13.4 months), the median PFS was 4.9 months (95% CI, 1.6-11.7 months). Among the responders, 8 of 14 patients subsequently underwent allogeneic hematopoietic cell transplantation.ConclusionCLAG plus IM was well tolerated, with encouraging signs of activity in patients with poor-risk AML.     

Daphnetin ameliorates 7,12-dimethylbenz[a]anthracene-induced mammary carcinogenesis through Nrf-2-Keap1 and NF-κB pathways

Cancer is a faction of disorders that conjugated primarily with oxidative imbalance. In mammary carcinoma, oxidative stress secondarily changes various gene expressions and signalling pathways that bring genomic instability and mutagenic alterations that fascinating carcinogenesis. Several coumarin compounds are active against various malignancies. Among them, daphnetin (DAP) exhibits valuable safety and bioactivity profile that contributes towards its efficacy against cancer. In this study, the antioxidative and chemotherapeutic potential of DAP against 7,12-dimethylbenz(a)anthracene (DMBA)- induced mammary carcinogenesis was evaluated in female Sprague-Dawley rats. Besides this, we have determined the effect of DAP on Keap1-Nrf-2, associated HO-1 and NF-κB expressions behind the antioxidative and anti-proliferating activity. In our findings, a protective effect of DAP was established against lipid peroxidation, enzymic (Total SOD, MnSOD, CuZnSOD, CAT, GPx) and non-enzymic (GSH) antioxidative markers in serum, liver, kidney and breast tissue of both control and experimental groups. An up-regulation of protective Nrf-2 & HO-1 with a synchronized suppression in Keap1 & NF-κB mRNA and protein expressions were observed. DAP revealed the inhibition of p-AKT which accountable for decrease in NF-κB expressions but shown to be ineffective on p-ERK1/2. This study revealed that DAP inhibits mammary carcinogenesis through multiple mechanisms. Dual efficacy of DAP on Nrf-2-Keap1 pathway and NF-κB expressions propose it as a potential chemotherapeutic agent in mammary cancer management.     

静脉用药调配中心全静脉营养液处方分析

目的对郑州人民医院近3个月全肠道外营养液（TPN）处方设计进行分析,为TPN临床合理应用提供参考。方法汇总郑州人民医院近3个月TPN处方并就其配方的成分组成进行统计分析。结果郑州人民医院近3个月TPN处方669张,设计基本合理,但仍存在非蛋白热卡不足、含氮量偏低等问题,经审核排除不合格用药处方张数55张,占总处方数的8.22%。结论临床医生应针对患者的营养状况准确,合理的设计TPN配方,提高临床营养治疗的安全性和有效性,同时药师应通过审方来进一步保证处方的合理性。     

胶类中药的特点及现代研究分析

动物胶类药物在很多疾病的治疗和保健中发挥重要作用。许多古籍中均有以胶类入方治疗疾病的记载。近年来，胶类药物的相关研究逐渐增多，应用领域也在不断扩大。笔者通过对常用胶类药物的发展变化、药性归经、现代药理作用、临床应用、胶类新药开发前景、质量控制方法等方面的分析总结，整理出胶类中药的发展变迁及现代研究进展，为今后胶类药物的开发利用提供参考。     

A self-guidance biological hybrid drug delivery system driven by anaerobes to inhibit the proliferation and metastasis of colon cancer

Colorectal cancer is often accompanied by multiple organ metastasis. Anaerobic Bifidobacterium Infantis (BI) bacterial can selectively grow in hypoxic colorectal tumor microenvironment (TME), to own the natural advantage of preferentially colorectal tumor targeting. Herein, a self-guidance biological hybrid drug delivery system (BI-ES-FeAlg/DOX) based on BI was constructed to inhibit the proliferation and metastasis of colon cancer. Results demonstrated that BI-ES-FeAlg/DOX could overcome physical barriers to target and accumulate in colon tumor tissues. Then DOX was released to kill tumor cells along with the phase transition (solid to liquid) of FeAlg hydrogel, due to Fe³⁺ was reduced to Fe²⁺by intracellular GSH. Meanwhile, BI-ES selectively colonized into tumors and expressed endostatin (ES) protein to down-regulate VEGF and bFGF expression, exerting anti-angiogenic effect. Moreover, FeAlg catalyzed H₂O₂ in the local tumor to generate cytotoxic ·OH, further enhancing the antitumor effect. The pharmacodynamic result in AOM/DSS model proved that BI-ES-FeAlg/DOX had the best therapeutic effect, with the final V/V₀ of 2.19 ± 0.57, which was significantly lower than the other groups. Meanwhile, on CT-26 tumor-bearing model, it also showed an outstanding anti-tumor effect with inhibition rate of 82.12% ± 3.08%. In addition, lung metastases decreased significantly in tumor metastasis model after BI-ES-FeAlg/DOX treatment.